

OCT 20 2004

SCHERING-PLOUGH CORPORATION

LAW DEPARTMENT

2000 GALLOPING HILL ROAD

K-6-1, MAIL STOP 1990

KENILWORTH, NEW JERSEY 07033

(908) 298-4000

FACSIMILE TRANSMITTAL SHEET

TO:

US Patent and Trademark Office
Attn: Examiner Shengjun Wang

FAX NUMBER:

(703) 872-9306

FROM:

Anita W. Magatti

PHONE NUMBER:

(908) 298-5067

TOTAL NO. OF PAGES INCLUDING COVER

18

DATE

October 20, 2004

CONFIDENTIALITY NOTE: This sheet and/or the document(s) accompanying it contain information belonging to Schering-Plough Corporation and/or its affiliates which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named above. If you have received this fax in error, please immediately notify us by telephone. If there is a problem with this transmission please call Rosa Scasso-Viola at (908) 298-4080.


NOTES/COMMENTS:

In re application of: Bahige M. Baroudy *et al.*
For the Patent Entitled: Piperazine Derivatives Useful as CCR5 Antagonists

Filed: 09/23/2003
Attorney Docket No.: IN01032K1C
Serial No.: 10/668,862

Transmitted herewith are:

- Supplementary Preliminary Amendment (16 pgs.)
- Fax Cover Sheet (1 pg.)
- Certificate of Transmission under 37 C.F.R. 1.8


Anita W. Magatti
Reg. No. 29,825

47304_1.DOC

PHONE: (908) 298-5067

FAX: (908) 298-5388

Attorney Docket No.: IN01032K1C

Application No.: 10/668,862

Filing Date: 09/23/2003

First Named Inventor: Bahige M. Baroudy et al.

PTO/SB/87 (08-03)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. 703-872-9306)

on October 20, 2004

Date


SignatureAnita W. Magatti, Reg. No. 29,825

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Document(s) being transmitted:

Supplementary Preliminary Amendment (16 pgs.)

Fax Cover Sheet (1 pg.)

Certificate of Transmission under 37 C.F.R. 1.8 (1 pg.)

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER

OCT 20 2004

PATENT
CASE IN01032K1C**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

-----X
In re Application of:
Bahige M. Baroudy et al

For Patent For:
Piperazine Derivatives Useful as
CCR5 Antagonists

Examiner: Shengjun Wang

Art Unit: 1617

Serial No.: 10/668,862

Filing Date: September 23, 2003

-----X
Schering-Plough Corporation
Kenilworth, New Jersey 07033-0530

Commissioner for Patents
PO Box 1450
Alexandria VA 22313-1450

SUPPLEMENTARY PRELIMINARY AMENDMENT

Sir:

Applicants submitted Preliminary Amendments at the time of filing this application. It is respectfully requested that before consideration on the merits, new claims 29-30 also be added.

In the following requested amendments to the claims, the descriptions of claims 1-14, 27 and 28 are the same as in the Preliminary Amendment filed with the case, i.e., claim 1 is "cancelled," claim 2 is "currently amended," etc, but the designations have been added to claims 15-26 since they were inadvertently omitted in the Preliminary Amendment.

Applicants further note that the original Preliminary Amendment updated the priority information in the specification, but that amendment is not repeated here.

Certificate of Transmission

I hereby certify that this correspondence is being facsimile
transmitted to the Patent and Trademark Office (Fax No. 703-872-9306) on
October 20, 2004,

(Date)

Typed or printed name of person signing this certificate.

Anita W. Magatti

(name)

Signature

